Scarica l'app Stockscreener
10.11
0.69%
-0.07
Dopo l'orario di chiusura:
10.20
0.09
+0.89%
Precedente Chiudi:
$10.18
Aprire:
$10.07
Volume 24 ore:
33,732
Relative Volume:
0.38
Capitalizzazione di mercato:
$66.56M
Reddito:
-
Utile/perdita netta:
$-31.48M
Rapporto P/E:
-9.7212
EPS:
-1.04
Flusso di cassa netto:
$-28.71M
1 W Prestazione:
+2.80%
1M Prestazione:
-31.04%
6M Prestazione:
-31.22%
1 anno Prestazione:
-31.46%
Intervallo 1D:
$10.02
$10.60
Intervallo di 1 settimana:
$9.12
$10.70
Portata 52W:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Nome
Forte Biosciences Inc
Settore
Industria
Telefono
(310) 618-6994
Indirizzo
3060 PEGASUS PARK DRIVE, DALLAS, CA
Confronta FBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.11 | 120.12M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Iniziato | TD Cowen | Buy |
| 2024-04-08 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Aggiornamento | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Downgrade | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Downgrade | Truist | Buy → Hold |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-03-26 | Iniziato | Citigroup | Buy |
| 2020-08-28 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Iniziato | Truist | Buy |
Mostra tutto
Forte Biosciences Inc Borsa (FBRX) Ultime notizie
What analysts say about Forte Biosciences Inc. stockConsistently high returns - Autocar Professional
Is Forte Biosciences Inc. a good long term investmentSuperior return velocity - Autocar Professional
What drives Forte Biosciences Inc. stock priceStrongest growth potential - PrintWeekIndia
Forte Biosciences Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
WVVI Stock Analysis and ForecastFree Bull & Bear Market Updates - Jammu Links News
Why Forte Biosciences Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Forte Biosciences Inc. stock price move sharplySafe Entry High Exit Alerts - Newser
How Forte Biosciences Inc. stock performs during market volatilityTop Momentum Stock Pick - Newser
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Forte Biosciences (FBRX): A Strategic Buy in Biotech's High-Reward Arena - AInvest
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Yahoo Finance
(FBRX) Investment Analysis and Advice - news.stocktradersdaily.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Index - MarketScreener
FBRX SEC FilingsForte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Stock Sell-Offs Trigger Market Turmoil For Firms - Finimize
Firm Advises Forte Biosciences on $75 Million Public Offering - Wilson Sonsini
Forte Biosciences (FBRX) Plans $75 Million Public Offering - GuruFocus
Forte Biosciences Prices $75 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq
Forte Biosciences Announces Public Offering of Shares - TipRanks
Forte’s celiac disease drug shows positive results in Phase 1b trial - Investing.com Nigeria
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - New Castle News
Forte Biosciences (FBRX) Soars 16.75% on Positive Clinical Trial Results - AInvest
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Forte Biosciences Inc Azioni (FBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):